Daniel Rutrick
Watertown, MANPI 1568499242
Payments from drug & device makers
$13,687,601in general payments, 2019–2025
Across 508 payments — averaging $26,944 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$5.4M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3.4M
- Boehringer Ingelheim International GmbH$2.1M
- AbbVie$1.4M
- Acadia Pharmaceuticals Inc$770K
- Sage Therapeutics, LLC$413K
- plus $258K from 4 others
$840in research payments, 2019–2025
Across 10 payments — averaging $84.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$630
- Otsuka Pharmaceutical Development & Commercialization, Inc.$210
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 199 | $5,397,700 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 14 | $3,403,936 |
| Boehringer Ingelheim International GmbH | 51 | $2,088,097 |
| AbbVie | 81 | $1,356,957 |
| Acadia Pharmaceuticals Inc | 44 | $770,283 |
| Sage Therapeutics, LLC | 67 | $412,563 |
| Sunovion Pharmaceuticals Inc. | 28 | $144,175 |
| Supernus Pharmaceuticals, Inc. | 9 | $104,366 |
| Indivior Inc. | 14 | $9,300 |
| Eli Lilly | 1 | $224 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.